Intracellular Distribution of Oligonucleotides Delivered by Cationic Liposomes: Light and Electron Microscopic Study1Katriina Lappalainena, Riitta Miettinenb, Jari Kellokoskic, Ilpo Jääskeläinend, and Stina Syrjänena,ea MediCity Research Laboratory, University of Turku, Turku, Finland b Department of Neurology, University of Kuopio, Kuopio, Finland c Department of Pathology, University of Kuopio, Kuopio, Finland d Pharmaceutical Technology, University of Kuopio, Kuopio, Finland e Department of Dentistry, University of Turku, Turku, Finland Correspondence to: Katriina Lappalainen, Department of Pathology, University of Kuopio, PO Box 1627, 70211 Kuopio, Finland.
Synthesized oligonucleotides are used in anti-sense and anti-gene technology to control gene expression. Because cells do not easily take up oligonucleotides, cationic liposomes have been employed to facilitate their transport into cells. Athough cationic liposomes have been used in this way for several years, the precise mechanisms of the delivery of oligonucleotides into cells are not known. Because no earlier reports have been published on the liposomal delivery of oligonucleotides at the ultrastructural level, we performed a study, using electron microscopy, on the cellular uptake and intracellular distribution of liposomal digoxigenin-labeled oligodeoxynucleotides (ODNs) at several concentrations (0.1, 0.2, and 1.0 µM) in CaSki cells. Two cationic lipids (10 µM) were compared for transport efficiency: polycationic 2,3-dioleoyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA) and monocationic dimethyl-dioctadecylammonium bromide (DDAB). Both liposomes contained dioleoyl-phosphatidylethanolamine (DOPE) as a helper lipid. Endocytosis was found to be the main pathway of cellular uptake of liposomal ODNs. After release from intracellular vesicles, ODNs were carried into the perinuclear area. The nuclear membrane was found to be a barrier against the penetration of ODNs delivered by liposomes into the nucleus. Release from vesicles and transport into the nuclear area was faster when the oligo-DDAB/DOPE complex had a positive net charge (0.1 and 0.2 µM ODN concentrations), and only under this condition were some ODNs found in nucleoplasm. Although DOSPA/DOPE could also efficiently deliver ODNs into the cytosol, no ODNs were found in nucleoplasm. These findings suggest that both the type of liposome and the charge of the oligo-liposome complex are important for determination of the intracellular distribution of ODNs. (J Histochem Cytochem 45:265-274, 1997) Key Words: Oligodeoxynucleotides, Anti-sense, Cationic liposomes, Digoxigenin label, CaSki cells, Electron microscopy, Electron immunocytochemistry
Oligonucleotides have been used for several years to control gene expression. They have also been shown to have potential as therapeutic agents. Several clinical trials are already in progress on their effectiveness in the treatment of acute myelogenous leukemia, human immunodeficiency virus, cytomegalovirus, and human papilloma virus infections (
Oligonucleotide-based techniques involve several problems, especially those associated with the stability, affinity, specificity, and cellular delivery of the oligos (
As for oligonucleotides, cationic liposomes have been widely used because of their several advantages over conventional delivery methods, such as spontaneous complex formation with negatively charged nucleic acids (
Although cationic liposomes have been successfully used as oligonucleotide carriers, the cellular uptake mechanisms and intracellular fate of liposomal oligonucleotides are not fully understood. Results from our previous studies suggest that liposomal ODNs are transported into the nucleus (
Cell Culture
ODNs and Liposomes
A commercial polycationic transfection reagent, LipofectAMINE (Gibco BRL) containing 2,3-dioleoyloxy-N-[2 (sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA) and dioleoyl-phosphatidylethanolamine (DOPE) (3/1 w/w) or a monocationic liposomal preparation containing dimethyldioctadecylammonium bromide (DDAB) and DOPE (2/5 w/w) was used. The liposomes containing DDAB and DOPE were prepared as described by
Incubation of DIG-ODNs and Cationic Liposomes in CaSki Cells
Immunocytochemistry Processing of CaSki Cells. After incubation with DIG-ODNs and cationic liposomes, CaSki cells were fixed in 3% paraformaldehyde (EM grade; TAAB, Berks, UK) and 0.5% glutaraldehyde (EM grade; TAAB) in 0.1 M phosphate buffer (PB, pH 7.4) for 15 min. After washings, the cells were treated with 1% NaBH4 for 5 min to reduce free aldehyde groups and double bonds. After extensive washings, CaSki cells were immersed in 25% sucrose in 0.05 M PB for 5 min and freeze-thawed three times using liquid nitrogen to increase the penetration of the antisera during immunostaining. Immunostaining. The samples were washed three times using 0.05 M Tris-buffered saline (TBS, pH 7.4). At the first washing, 0.2% Triton X-100 in TBS was used for 5 min. After incubation in 10% normal goat serum (NGS, 15 min) in TBS and washing in 1% NGS in TBS, the samples were incubated with horseradish peroxidase-conjugated anti-DIG antibody Fab fragments (anti-DIG-POD, 1:500; Boehringer Mannheim, Pentzberg, Germany) in 1% NGS in TBS at 4°C overnight. The immunoperoxidase reaction was developed using 3,3'-diaminobenzidine hydrochloride (DAB) as chromogen. Controls. Three controls were used: (a) cells without DIG-ODNs and liposomes; (b) cells with cationic liposomes, but without oligonucleotides; and (c) cells treated with liposomal DIG-ODNs, omitting anti-DIG incubation during immunostaining.
Sample Preparation for Light Microscopy.
After immunostaining, the immunoperoxidase reaction product was intensified using 0.02% OsO4'PS8 Sample Preparation for Electron Microscopy (EM). After immunostaining, the samples were treated with 1% OsO4 in PB for 1 hr. After staining with 2% uranyl acetate and dehydration, the samples were embedded in Epon (Fluka; Buchs, Switzerland). Ultrathin sections were cut on copper grids and stained with uranyl acetate and lead citrate. Some sections were left unstained for detection of any immunoperoxidase reaction in the nucleus. The sections were analyzed using JEOL JEM-1200 EX transmission EM. The experiments were performed twice in duplicate for electron microscopy. Many sections were cut from the samples for screening the intracellular localization of immunopositivity.
Immunopositive Signals on Plasma Membrane After 5 Min of Incubation
The immunopositive signals were strongest after 1.0 µM DIG-ODN and DDAB/DOPE treatment. Signals from DIG-ODNs delivered by DDAB/DOPE were more intense earlier (5 min, 20 min, 1.5 hr) than those delivered by DOSPA/DOPE, as seen with CaSki cells after 20 min of incubation with liposomal DIG-ODNs in Figure 1B and Figure 1C. Most cells (over 95%) contained immunopositivity after 1.5-hr incubation of 1.0 µM DIG-ODN with DDAB/ DOPE (Figure 1E). However, some immunopositivity from DIG-ODNs delivered using DOSPA/DOPE was also seen in the cytoplasm and perinuclear (or nuclear) area after 20 min (Figure 1C) and 1.5 hr of incubation, respectively. The difference disappeared after 4 hr (Figure 1E and Figure 1F), and after 24 hr the signals were slightly more intense from DIG-ODNs delivered using DOSPA/DOPE (Figure 1I) than from those delivered using DDAB/DOPE (Figure 1H). At ODN concentrations of 0.1 and 0.2 µM, only weak immunopositivity was seen with DOSPA/DOPE in CaSki cells, whereas intense immunoreactivity was seen with DDAB/DOPE. When cationic liposomes were not used, DIG-ODNs showed only weak immunoreactivity at all concentrations and observation times. Immunopositivity for liposomal random DIG-ODN was similar to that for liposomal anti-sense DIG-ODN.
Immunoreactivity in Intracellular Vesicles
Differences in Intracellular Distribution CaSki cells treated with DIG-ODNs at concentrations of 0.1 or 0.2 µM and DDAB/DOPE (when the oligo-lipid complexes were positive; Table 1) showed immunopositivity in their cytosol and perinuclear areas after only 1.5 hr of incubation (Figure 2I). The important finding was that although most immunopositivity was located on the nuclear envelope, some was also seen in the nucleoplasm after 4 hr of incubation (Figure 2J). After 24 hr of incubation, staining was less intense and no immunopositivity was seen in the nucleoplasm (Figure 2K and Figure 2L). Treatment of cells with ODNs (0.1, 0.2 or 1.0 µM) and DOSPA/DOPE (when the oligo-lipid complexes were positive; Table 1) did not produce any immunoreactivity in the nucleoplasm at any observation time. By contrast, immunoreactivity in the cytosol and nuclear membrane weakened with decreasing oligo concentrations and was similar to that in the DDAB/DOPE delivery system.
General Morphological Observations
The most important findings of the present study were as follows: (a) liposomal ODNs are efficiently taken up by endocytosis irrespective of the charge of the ODN/liposome complex; (b) the charge of the ODN-DDAB/DOPE complex and the type of liposome affected intracellular distribution; and (c) the nuclear envelope was a barrier against the penetration of ODNs delivered by liposomes into the nucleus of CaSki cells.
Our study showed that both negatively and positively charged oligo-liposome complexes were rapidly and effectively taken up during endocytosis, released into the cytosol, and transported into the perinuclear area. Both polycationic and monocationic liposomes transferred ODNs along the endocytotic pathway. This is in agreement with recent studies in which the main route of liposomal DNA was found to be endocytosis and thereafter its release into cytosol (
In the presence of DDAB/DOPE, more ODNs were seen inside CaSki cells when ODNs were used at the highest concentration (1.0 µM). By contrast, at lower concentrations (0.1 and 0.2 µM), ODNs were released from intracellular vesicles into the cytosol and carried more rapidly into the perinuclear area. This suggests that ODNs are released more rapidly from intracellular vesicles into the cytosol if the oligo-liposome complex has a positive net charge, as shown with model membranes (
ODNs were delivered more rapidly into cells with DDAB/DOPE than with DOSPA/DOPE. At lower ODN concentrations (0.1 and 0.2 µM), DDAB/DOPE de-livered ODNs more effectively than DOSPA/DOPE did, although no remarkable differences occurred at higher concentration. Because our immmunocytochemical method is only semiquantitative, no firm conclusions can be drawn about the amount of intracellular ODNs. One explanation for the difference in delivery effectiveness may be that the amount of the helper lipid DOPE was lower in the DOSPA/DOPE preparation than in the DDAB/DOPE preparation. According to our measurements, particles were smaller in DOSPA/DOPE than DDAB/DOPE. The small particle size (<5 nm) has been reported to correspond with micelles rather than with liposomes (
Our EM study showed no ODNs inside CaSki cells incubated without cationic liposomes. However, the weak immunoreactivity in CaSki cells detected in light microscopy after incubation with ODNs but without liposomes suggests that some non-liposomal ODNs can be taken up by CaSki cells. Recently, a study at the ultrastructural level demonstrated non-liposomal ODNs in intracellular vesicles, indicating that the cellular uptake of ODNs also depends on endocytosis (
Using EM, our study is the first to show that the nuclear envelope can form a barrier against the penetration of liposomal ODNs into the nucleus of CaSki cells. This might be explained by the persisting association of ODNs with liposomes after release into the cytosol (
Only a few studies have investigated the nuclear localization of ODNs at the EM level (
Because the intracellular distribution may vary according to the cell type, each delivery system should be tested in the cells that would be the target cells in vivo. The CaSki cells used in the present study are known to contain human papillomavirus (HPV) DNA. Several molecular biological and epidemiological data have, in turn, provided evidence for the role of HPV infection in cervical cancer (
1 Supported by a research contract from the Medical Research Council of the Academy of Finland, by the Finnish Cancer Fund, Research and Science Foundation of Farmos, and by the Finnish Cultural Foundation.
Arens MJ, Wyllie AH, Bird CC (1995) Human papillomavirus type 18 is associated with less apoptosis in fibroblast tumours than human papillomavirus type 16. Br J Cancer 72:646-649[Medline] Beltinger C, Saragovi HU, Smith RM, LeSauteur L, Shah N, DeDionisio L, Christensen L, Raible A, Jarett L, Gewirtz AM (1995) Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligonucleotides. J Clin Invest 95:1814-1823 Bennett CF, Chiang MY, Chan H, Shoemaker JEE, Mirabelli CK (1992) Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 41:1023-1033[Abstract] Breitburd FV (1987) Cell culture systems for the study of papillomaviruses. In Syrjänen K, Gissmann L, Koss LG, eds. Papillomaviruses and Human Disease. Berlin, Heidelberg, Springer-Verlag, 371-392 Capaccioli S, Di Pasquale G, Mini E, Mazzei T, Quattrone A (1993) Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. Biochem Biophys Res Commun 197:818-825[Medline] Farhood H, Serbina N, Huang L (1995) The role of dioleoylphosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim Biophys Acta 1235:289-295[Medline]
Friend DS, Debs RJ, Duzunes N (1990) Interactions between DOTMA liposomes, CV-1 and U937 cells and their isolated nuclei. J Cell Biol 111:663
Gura T (1995) Antisense has growing pains. Science 270:575-577
Hanvey JC, Peffer NJ, Bisi JE, Thomson SA, Cadilla R, Josey JA, Ricca DJ, Hassman CF, Bonham MA, Au KG, Carter SG, Bruckenstein DA, Boyd AL, Noble SA, Babiss LE (1992) Antisense and antigene properties of peptide nucleic acids. Science 258:1481-1485 Hawley-Nelson P, Ciccarone V, Gebeyehu G, Jessee J, Felgner PL (1993) LipofectAMINEM reagent: a new higher efficiency polycationic liposome transfection reagent. Focus 15:73-79 Helene C (1994) Control of oncogene expression by antisense nucleic acids. Eur J Cancer 30:1721-1726 Höltke HJ, Sagner G, Kessler C, Schmitz G (1992) Sensitive chemiluminescent detection of digoxigenin labeled nucleic acids: a fast and simple protocol and its applications. Biotechniques 12:104-113[Medline] Jääskeläinen I, Mönkkönen J, Urtti A (1994) Oligonucleotide-cationic liposome interactions. A physicochemical study. Biochim Biophys Acta 1195:115-123[Medline] Lappalainen K, Jääskeläinen I, Syrjänen K, Urtti A, Syrjänen S (1994a) Comparison of cell proliferation and toxicity assays using two cationic liposomes. Pharmaceut Res 11:1127-1131[Medline] Lappalainen K, Urtti A, Söderling E, Jääskeläinen I, Syrjänen K, Syrjänen S (1994b) Cationic liposomes improve stability and intracellular delivery of antisense oligonucleotides into CaSki cells. Biochim Biophys Acta 1196:201-208[Medline]
Lasic DD, Papahadjopoulos D (1995) Liposomes revisited. Science 267:1275-1276
Lowy DR, Kirnbauer R, Schiller JT (1994) Genital human papillomavirus in anogenital cancer. Proc Natl Acad Sci USA 91:2436-2440
Perez JR, Li Y, Stein CA, Majumder S, von Oorschot A, Narayanan R (1994) Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci USA 91:5957-5961 Plenat F, Klein-Monhoven N, Marie B, Vignaud JM, Duprez A (1995) Cell and tissue distribution of synthetic oligonucleotides in healthy and tumor-bearing nude mice. Am J Pathol 147:124-135[Abstract] Rose JK, Buonocore L, Whitt MA (1991) A new cationic liposome reagent mediating nearly quantitative transfection of animal cells. Biotechniques 10:520-525[Medline] Scanlon KJ, Ohta Y, Ishida H, Kijima H, Ohkawa T, Kaminski A, Horng G, Kashani-Sabet M (1995) Oligonucleotide-mediated modulation of mammalian gene expression. FASEB J 9:1288-1296[Abstract] Singhal A, Huang L (1994) Gene transfer in mammalian cells using liposomes as carriers. In Wolff JA, ed. Gene Therapeutics, Methods and Applications of Direct Gene Transfer. Boston, Birkhüser, 118-142 Smith JG, Walzem RL, German JB (1993) Liposomes as agents of DNA transfer. Biochim Biophys Acta 1154:327-340[Medline] Solodin I, Brown CS, Bruno MS, Chow C-Y, Jang E-H, Debs RJ, Heath TD (1995) A novel series of amphiphilic imidazolinium compounds for in vitro and in vivo gene delivery. Biochemistry 34:13537-13544[Medline] Stull RA, Szoka FC, Jr (1995) Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects. Pharmaceut Res 12:465-483[Medline] Tarrasón G, Bellido D, Eritja R, Vilaro S, Piulats J (1995) Digoxigenin-labeled phosphorothioate oligonucleotides: a new tool for the study of cellular uptake. Antisense Res Dev 5:193-201[Medline] Wagner RW (1994) Gene inhibition using antisense oligodeoxynucleotides. Science 372:333-335
Wagner RW, Matteucci MD, Lewis JG, Guttierrez AJ, Moulds C, Froehler BC (1993) Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science 260:1510-1513 Wittung P, Kajanus J, Edwards K, Haaima G, Nielsen PE, Norden B, Malmström BG (1995) Phospholipid membrane permeability of peptide nucleic acid. FEBS Lett 375:27-29[Medline] Wrobel I, Collins D (1995) Fusion of cationic liposomes with mammalian cells occurs after endocytosis. Biochim Biophys Acta 1235:296-304[Medline] Yee F, Ericson H, Reis DJ, Wahlestedt C (1994) Cellular uptake of intracerebroventricularly administered biotin- or digoxigenin-labelled antisense oligodoxynucleotides in the rat. Cell Mol Neurobiol 14:475-486[Medline]
Zabner J, Fasbender AJ, Moninger T, Poellinger KA, Welsh MJ (1995) Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem 270:18997-19007
Zamecnik P, Aghajanian J, Zamecnik M, Goodchild J, Witman G (1994) Electron micrographic studies of transport of oligodeoxynucleotides across eucaryotic cell membranes. Proc Natl Acad Sci USA 91:3156-3160 Zhou X, Huang L (1994) DNA transfection mediated by cationic liposomes containing lipopolylysine: characterization and mechanism of action. Biochim Biophys Acta 1189:195-203[Medline] zur Hausen H (1991) Human papillomavirus in the pathogenesis of anogenital cancer. Virology 184:9-13[Medline]
This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||